clinic
front
two
key
requir
pandem
reduc
infect
rate
decreas
death
rate
infect
whilst
major
effort
aim
infect
also
need
clinic
research
best
manag
serious
ill
patient
current
avail
therapi
includ
nonspecif
antivir
antibiot
treat
secondari
bacteri
infect
sepsi
corticosteroid
reduc
inflamm
fail
sever
diseas
hallmark
cytokin
storm
induc
lung
visibl
inflammatori
lesion
groundglass
opac
ct
scan
virallytrigg
acut
cytokin
releas
gscf
induc
pulmonari
oedema
dysfunct
airexchang
acut
respiratori
distress
syndrom
acut
cardiac
injuri
often
secondari
infect
lead
death
lancet
recent
publish
first
comprehens
clinic
data
risk
factor
mortal
detail
clinic
cours
ill
includ
viral
shed
may
continu
survivor
day
inhospit
death
associ
age
notabl
signific
correl
case
fatal
rate
cfr
remain
unknown
number
infect
determin
estim
higher
influenza
accru
epidemiolog
analys
link
countrybas
mitig
strategi
estim
patient
mild
asymptomat
diseas
sever
diseas
critic
ill
underpin
continu
need
treatment
pneumonia
long
term
two
recent
studi
china
ask
mesenchym
stem
cell
msc
treat
pneumonia
base
known
immunomodulatori
repar
properti
stem
cell
studi
reveal
remark
revers
symptom
even
severecrit
condit
accordingli
clinic
studi
identifi
novel
therapeut
strategi
also
exist
natur
mechan
abl
counteract
acut
inflammatori
pneumonia
one
studi
case
report
critic
ill
patient
ventil
progress
despit
intens
therapi
marker
show
evid
liver
injuri
patient
treat
allogen
human
umbil
cord
msc
hucmsc
use
three
intraven
infus
hucmsc
three
day
apart
within
four
day
second
cell
infus
patient
ventil
abl
walk
measur
paramet
includ
circul
cell
count
return
toward
normal
levelslymphocyt
previous
low
presum
due
sequestr
within
inflam
lung
tissu
obviou
side
effect
observ
second
studi
pilot
clinic
trial
assess
whether
msc
transplant
could
improv
outcom
enrol
patient
clinic
pneumonia
one
critic
sever
four
sever
nonsever
transplant
high
fever
short
breath
low
oxygen
satur
treatment
singl
intraven
dose
clinic
grade
msc
cell
per
kilogram
weight
detail
followup
day
posttransplant
show
advers
effect
within
day
patient
significantli
improv
pulmonari
function
includ
one
sever
pneumonia
case
well
enough
discharg
day
full
detail
present
overal
treatment
peripher
lymphocyt
increas
shift
toward
regulatori
phenotyp
cell
dendrit
cell
inflammatori
cytokin
significantli
decreas
whilst
increas
clinic
msc
trial
also
ask
infect
therapeut
msc
cell
enter
cell
receptor
wide
distribut
human
cell
includ
alveolar
capillari
endothelium
msc
neg
initi
followup
use
rnaseq
survey
identifi
transplant
msc
reveal
cell
differenti
still
remain
neg
thu
presum
free
moreov
remark
gene
express
profil
recov
msc
show
high
antiinflammatori
trophic
factor
activ
includ
hgf
lif
vegf
egf
bdnf
ngf
demonstr
immunomodulatori
properti
msc
longterm
activ
maintain
continu
cytokin
product
howev
whilst
msc
studi
identifi
new
approach
treat
pneumonia
practic
overwhelm
scale
number
patient
need
treat
argu
cell
therapi
logist
ground
solut
novel
approach
captur
therapeut
properti
stem
cell
use
nanotechnolog
becom
immedi
relev
lif
leukaemia
inhibitori
factor
known
indispens
oppos
cytokin
storm
lung
viral
pneumonia
fig
although
msc
releas
lif
solut
fail
due
cellbas
whilst
carri
prohibit
cost
burden
use
nanotechnolog
synthet
stem
cell
avail
lifnano
time
increas
potenc
compar
solubl
lif
eae
preclin
model
multipl
sclerosi
ms
treatment
lifnano
trevers
paralysi
within
day
fig
time
line
accord
report
benefici
effect
pneumonia
use
msc
therapi
previou
studi
use
neural
stem
cell
nsc
treat
eae
show
benefit
sole
depend
nscderiv
lif
review
emerg
altern
cellbas
therapi
lifnano
meet
need
high
volum
offtheshelf
therapeut
agent
abl
rejuven
damag
tissu
suppress
cytokin
storm
pneumonia
global
distribut
simpl
use
low
volum
vial
option
deliveri
rout
includ
inhal
intraven
whilst
new
vaccin
reduc
infect
rate
develop
scale
need
treat
signific
number
patient
develop
pneumonia
remark
new
data
use
msc
demonstr
success
har
natur
endogen
pathway
power
protect
properti
age
growth
factor
associ
stem
declin
favour
inflammatori
cytokin
includ
correl
inhospit
death
result
pneumonia
therapi
remov
inflammatori
mediat
clearanc
antibodi
may
fail
achiev
critcal
balanc
endogen
antivir
respons
ii
control
endogen
protect
repar
action
lif
excess
cytokin
storm
consid
need
mitig
current
pandem
prioriti
keep
mortal
low
possibl
find
msc
safe
revers
sever
critic
diseas
high
potenc
major
breakthrough
repres
entir
new
biolog
approach
treatment
need
develop
urgent
end
stem
cell
biotech
compani
join
forc
eg
athersi
mesoblast
whilst
nanotechnologybas
synthet
stem
cell
lifnano
readi
cgmp
product
scale
today
research
receiv
specif
grant
fund
agenc
public
commerci
notforprofit
sector
credit
authorship
contribut
statement
su
metcalf
write
origin
draft
author
report
compet
interest
previou
studi
shown
lif
particularli
import
epitheli
activ
capac
pneumon
alveolar
line
treatment
exogen
lif
lif
overexpress
limit
pulmonari
inflamm
respons
lp
hyperoxia
quinton
experi
illustr
investig
requir
endogen
lif
protect
acut
lung
injuri
lung
collect
mice
h
intratrach
inocul
escherichia
coli
coinstil
antilif
control
signific
recoveri
movement
improv
prolong
therapi
result
highli
reproduc
control
nanoparticl
without
lif
cargo
target
effect
paralysi
studi
part
iuk
bmc
project
cellfre
regen
medicin
nanoengin
lifnano
treat
multipl
sclerosi
project
number
